Published in Curr Opin HIV AIDS on May 01, 2016
Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV) (BLIR-HIV) | NCT01228318
Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss (APART) | NCT02322099
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med (2003) 14.60
A TH1-->TH2 switch is a critical step in the etiology of HIV infection. Immunol Today (1993) 10.43
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (1997) 8.59
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest (1999) 7.66
Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature (2000) 6.49
Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med (2006) 5.63
Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS (2006) 5.58
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis (2010) 5.35
Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med (2001) 3.69
Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One (2012) 3.68
Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab (2008) 3.64
Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest (2006) 3.45
Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS (2013) 3.30
Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest (2000) 3.15
Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med (1999) 3.07
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr (2009) 2.75
HIV infection and bone mineral density in middle-aged women. Clin Infect Dis (2006) 2.67
Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol (2001) 2.65
B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol (2006) 2.56
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr (2010) 2.47
Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci U S A (1991) 2.44
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (2014) 2.27
Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J Clin Invest (1997) 2.23
B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood (2007) 2.16
IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest (2006) 2.15
Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 beta. J Immunol (1985) 2.02
Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS (2007) 1.95
Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis (2011) 1.83
Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS (2003) 1.80
IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci U S A (2002) 1.65
Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss. Nat Commun (2015) 1.63
Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis (2013) 1.49
Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS (2009) 1.46
Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS (2012) 1.45
T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J Bone Miner Res (2001) 1.43
CLINICAL Review # : low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab (2007) 1.42
Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A (2010) 1.38
Dual modulation of osteoclast differentiation by lipopolysaccharide. J Bone Miner Res (2002) 1.34
Incident fractures in HIV-infected individuals: a systematic review and meta-analysis. AIDS (2013) 1.31
RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. J Med Virol (2007) 1.26
Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr (2015) 1.25
Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients. J Acquir Immune Defic Syndr (2011) 1.24
Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antivir Ther (2011) 1.23
Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis (2013) 1.23
Fractures after antiretroviral initiation. AIDS (2012) 1.21
Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. PLoS One (2012) 1.19
Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab (2009) 1.16
An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc Natl Acad Sci U S A (2005) 1.13
Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy. J Bone Miner Res (2013) 1.03
Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients. J Transl Med (2013) 1.03
Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection. PLoS Pathog (2014) 1.03
Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology (1993) 1.02
Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis (2005) 1.00
CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut (2005) 1.00
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. J Infect Dis (2015) 0.99
Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy. J Acquir Immune Defic Syndr (2014) 0.99
Prominent bone loss mediated by RANKL and IL-17 produced by CD4+ T cells in TallyHo/JngJ mice. PLoS One (2011) 0.97
The role of HIV and antiretroviral therapy in bone disease. AIDS Rev (2011) 0.97
Relative contribution of HIV infection, demographics and body mass index to bone mineral density. AIDS (2014) 0.90
Low bone mineral density in patients with well-suppressed HIV infection: association with body weight, smoking, and prior advanced HIV disease. J Infect Dis (2014) 0.90
The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum (2004) 0.89
Effects of HIV infection and antiretroviral therapy with ritonavir on induction of osteoclast-like cells in postmenopausal women. Osteoporos Int (2010) 0.89
Immunology of Osteoporosis: A Mini-Review. Gerontology (2015) 0.88
Osteopenia in X-linked hyper-IgM syndrome reveals a regulatory role for CD40 ligand in osteoclastogenesis. Proc Natl Acad Sci U S A (2007) 0.87
Polymorphisms in the inflammatory genes CIITA, CLEC16A and IFNG influence BMD, bone loss and fracture in elderly women. PLoS One (2012) 0.87
Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study. AIDS (2014) 0.87
CTLA-4Ig-induced T cell anergy promotes Wnt-10b production and bone formation in a mouse model. Arthritis Rheumatol (2014) 0.86
Granulocyte-macrophage colony stimulating factor suppresses lipopolysaccharide-induced osteoclast-like cell formation in mouse bone marrow cultures. Endocrinology (1994) 0.86
T-cells and B-cells in osteoporosis. Curr Opin Endocrinol Diabetes Obes (2014) 0.84
A cross-sectional randomised study of fracture risk in people with HIV infection in the probono 1 study. PLoS One (2013) 0.83
Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults. AIDS (2015) 0.81
Microbial translocation and metabolic and body composition measures in treated and untreated HIV infection. AIDS Res Hum Retroviruses (2013) 0.79
Interleukin-17 regulates visceral obesity in HIV-1-infected patients. HIV Med (2012) 0.79
Effects of 96 Weeks of Rosuvastatin on Bone, Muscle, and Fat in HIV-Infected Adults on Effective Antiretroviral Therapy. AIDS Res Hum Retroviruses (2015) 0.78
Osteoporosis and fracture risk associated with HIV infection and treatment. Endocrinol Metab Clin North Am (2014) 0.76
Effect of interleukin-6 polymorphism on fracture risk. Int J Clin Exp Med (2015) 0.75
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis (2011) 3.38
Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS (2003) 2.97
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood (2013) 2.72
IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood (2009) 2.50
Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women. J Infect Dis (2012) 2.16
HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am J Clin Pathol (2006) 2.10
Comparison of the diversity of the vaginal microbiota in HIV-infected and HIV-uninfected women with or without bacterial vaginosis. J Infect Dis (2008) 1.99
Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis (2009) 1.95
The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS (2011) 1.94
Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS (2010) 1.83
Virological and immunological characteristics of human cytomegalovirus infection associated with Alzheimer disease. J Infect Dis (2013) 1.80
Aging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. Aging Cell (2012) 1.71
T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis (2011) 1.64
Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology (2007) 1.63
Multisite comparison of high-sensitivity multiplex cytokine assays. Clin Vaccine Immunol (2011) 1.62
HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS (2012) 1.55
The effect of aging on T-regulatory cell frequency in HIV infection. Clin Immunol (2008) 1.55
Exploratory comparison of vaginal glycogen and Lactobacillus levels in premenopausal and postmenopausal women. Menopause (2015) 1.49
Stat5 expression is critical for mast cell development and survival. Blood (2003) 1.48
Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS (2010) 1.46
Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr (2003) 1.44
Treatment-related changes in serum lipids and inflammation: clinical relevance remains unclear. Analyses from the Women's Interagency HIV study. AIDS (2013) 1.43
A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One (2011) 1.43
Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment. J Acquir Immune Defic Syndr (2012) 1.37
VACUTAINER CPT and Ficoll density gradient separation perform equivalently in maintaining the quality and function of PBMC from HIV seropositive blood samples. BMC Immunol (2006) 1.36
HIV and HAART-Associated Dyslipidemia. Open Cardiovasc Med J (2011) 1.34
Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis (2004) 1.33
Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection. Arterioscler Thromb Vasc Biol (2014) 1.32
Regulatory T cells in HIV infection: pathogenic or protective participants in the immune response? AIDS (2008) 1.30
Identification of rhesus macaque genital microbiota by 16S pyrosequencing shows similarities to human bacterial vaginosis: implications for use as an animal model for HIV vaginal infection. AIDS Res Hum Retroviruses (2010) 1.29
Antibody-dependent cell-mediated cytotoxicity in cervical lavage fluids of human immunodeficiency virus type 1--infected women. J Infect Dis (2002) 1.29
PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes. Clin Immunol (2008) 1.28
The effects of commensal bacteria on innate immune responses in the female genital tract. Am J Reprod Immunol (2010) 1.26
Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women. PLoS One (2013) 1.24
Activation of plasmacytoid dendritic cells with TLR9 agonists initiates invariant NKT cell-mediated cross-talk with myeloid dendritic cells. J Immunol (2006) 1.18
Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands. Cell Immunol (2008) 1.18
Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrob Agents Chemother (2009) 1.16
Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals. Clin Immunol (2006) 1.16
Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clin Immunol (2010) 1.09
Soluble CD163 is associated with noninvasive measures of liver fibrosis in hepatitis C virus- and hepatitis C virus/human immunodeficiency virus-infected women. Hepatology (2015) 1.09
Pyrosequencing of the genital microbiotas of HIV-seropositive and -seronegative women reveals Lactobacillus iners as the predominant Lactobacillus Species. Appl Environ Microbiol (2010) 1.04
Impact of mitochondrial toxicity of HIV-1 antiretroviral drugs on lipodystrophy and metabolic dysregulation. Curr Pharm Des (2010) 1.03
Invariant NKT cells from HIV-1 or Mycobacterium tuberculosis-infected patients express an activated phenotype. Clin Immunol (2008) 1.03
Short-chain fatty acids induce pro-inflammatory cytokine production alone and in combination with toll-like receptor ligands. Am J Reprod Immunol (2011) 1.01
Association of subclinical atherosclerosis with lipid levels amongst antiretroviral-treated and untreated HIV-infected women in the Women's Interagency HIV study. Atherosclerosis (2012) 1.01
Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J Antimicrob Chemother (2005) 1.00
Stat5: an essential regulator of mast cell biology. Mol Immunol (2002) 0.99
Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Res Hum Retroviruses (2002) 0.98
Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy. J Infect Dis (2011) 0.98
Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Immunology (2007) 0.98
Platelet function and HIV: a case-control study. AIDS (2010) 0.97
Genotyping of urogenital Chlamydia trachomatis in Regional New South Wales, Australia. Sex Transm Dis (2008) 0.96
Multiplex immunoassay of lower genital tract mucosal fluid from women attending an urban STD clinic shows broadly increased IL1ß and lactoferrin. PLoS One (2011) 0.95
GB virus C particles inhibit T cell activation via envelope E2 protein-mediated inhibition of TCR signaling. J Immunol (2013) 0.94
IL-10 inhibits Fc epsilon RI expression in mouse mast cells. J Immunol (2004) 0.94
Positive association between HIV RNA and IL-6 in the genital tract of Rwandan women. AIDS Res Hum Retroviruses (2008) 0.94
MDSC: a new player in HIV immunopathogenesis. AIDS (2012) 0.93
Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus. J Infect Dis (2013) 0.92
Advances in CD4 cell enumeration in resource-poor countries. Curr Opin HIV AIDS (2007) 0.91
HIV infection and aging of the innate immune system. Sex Health (2011) 0.91
Longitudinal assessment of pigtailed macaque lower genital tract microbiota by pyrosequencing reveals dissimilarity to the genital microbiota of healthy humans. AIDS Res Hum Retroviruses (2012) 0.91
Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study. J Clin Endocrinol Metab (2013) 0.90
The expression of cholesterol metabolism genes in monocytes from HIV-infected subjects suggests intracellular cholesterol accumulation. J Infect Dis (2012) 0.90
Dendritic cell activation and maturation induced by mucosal fluid from women with bacterial vaginosis. Clin Immunol (2007) 0.90
Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Res Hum Retroviruses (2009) 0.90
Relative contribution of HIV infection, demographics and body mass index to bone mineral density. AIDS (2014) 0.90
TLR2-activated B cells are phenotypically similar to the abnormal circulating B cells seen preceding the diagnosis of AIDS-related NHL diagnosis. J Acquir Immune Defic Syndr (2013) 0.89
Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection. J Infect Dis (2012) 0.88
Interleukin-4 elicits apoptosis of developing mast cells via a Stat6-dependent mitochondrial pathway. Exp Hematol (2004) 0.86
Associations of insulin-like growth factor (IGF)-I and IGF-binding protein-3 with HIV disease progression in women. J Infect Dis (2008) 0.85
Innate immune defenses in HIV-1 infection: prospects for a novel immune therapy. Expert Rev Anti Infect Ther (2006) 0.84
Characterization of CD4⁺ T-cell immune activation and interleukin 10 levels among HIV, hepatitis C virus, and HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr (2013) 0.84
Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. AIDS (2013) 0.83
High-density lipoprotein levels and 10-year cardiovascular risk in HIV-1-infected patients. AIDS (2011) 0.83
Saliva can mediate HIV-1-specific antibody-dependent cell-mediated cytotoxicity. FEMS Immunol Med Microbiol (2006) 0.83
The effects of untreated and treated HIV infection on bone disease. Curr Opin HIV AIDS (2014) 0.82
Viremic and Virologically Suppressed HIV Infection Increases Age-Related Changes to Monocyte Activation Equivalent to 12 and 4 Years of Aging, Respectively. J Acquir Immune Defic Syndr (2015) 0.82
HIV infection and bone disease: implications for an aging population. Sex Health (2011) 0.82
Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports. Clin Infect Dis (2008) 0.81
Relationship of HIV RNA and cytokines in saliva from HIV-infected individuals. FEMS Immunol Med Microbiol (2005) 0.81
Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women. J Acquir Immune Defic Syndr (2014) 0.80
Transient increase of interferon-stimulated genes and no clinical benefit by chloroquine treatment during acute simian immunodeficiency virus infection of macaques. AIDS Res Hum Retroviruses (2013) 0.80
Characterization of quantitative and functional innate immune parameters in HIV-1-infected Colombian children receiving stable highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 0.80
Effect of mucosal fluid from women with bacterial vaginosis on HIV trans-infection mediated by dendritic cells. Virology (2008) 0.80
HIV-associated mucosal gene expression: region-specific alterations. AIDS (2015) 0.79
Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy. J Acquir Immune Defic Syndr (2014) 0.79
IL-22 levels are associated with Trichomonas vaginalis infection in the lower genital tract. Am J Reprod Immunol (2013) 0.78
Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA. AIDS (2012) 0.78
Therapeutic approaches to combating lipoatrophy: do they work? J Antimicrob Chemother (2005) 0.78
Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy. Antivir Ther (2005) 0.78
Effects of Succinic Acid and Other Microbial Fermentation Products on HIV Expression in Macrophages. Biores Open Access (2013) 0.77
Short communication: Apoptosis pathways in HIV-1-infected patients before and after highly active antiretroviral therapy: relevance to immune recovery. AIDS Res Hum Retroviruses (2014) 0.77
Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181. Clin Vaccine Immunol (2010) 0.77